BioCryst Pharmaceuticals, Inc. (BCRX)
| Market Cap | 1.80B |
| Revenue (ttm) | 503.49M |
| Net Income (ttm) | -53.47M |
| Shares Out | 209.25M |
| EPS (ttm) | -0.26 |
| PE Ratio | n/a |
| Forward PE | 27.04 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,105,383 |
| Open | 8.79 |
| Previous Close | 8.70 |
| Day's Range | 8.52 - 8.79 |
| 52-Week Range | 6.02 - 11.31 |
| Beta | 1.04 |
| Analysts | Strong Buy |
| Price Target | 16.70 (+93.96%) |
| Earnings Date | Aug 4, 2025 |
About BCRX
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhib... [Read more]
Financial Performance
In 2024, BioCryst Pharmaceuticals's revenue was $450.71 million, an increase of 36.00% compared to the previous year's $331.41 million. Losses were -$88.88 million, -60.77% less than in 2023.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for BCRX stock is "Strong Buy." The 12-month stock price target is $16.7, which is an increase of 93.96% from the latest price.
News
BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit
RESEARCH TRIANGLE PARK, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new findings from patient-focused research h...
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development
RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head o...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted e...
BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million
—Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones— —BioCryst plans to use proceeds to retire...
BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI
—Data across pediatric, adolescent, and adult populations demonstrate sustained reductions in HAE attacks and consistent safety profile—
ORLADEYO® (berotralstat) Approved in Colombia
RESEARCH TRIANGLE PARK, N.C., June 13, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the National Institute of Drug and Food Surveillance (INVIMA) in Colo...
BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries
RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland...
BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology
RESEARCH TRIANGLE PARK, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that new data on oral, once-daily ORLADEYO® (berotralstat) for the prophyl...
BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages
New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supports berotralstat use at all stages of life New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supp...
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:
BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)
RESEARCH TRIANGLE PARK, N.C., May 16, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotrals...
BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years
–FDA grants Priority Review of application, with PDUFA target action date of September 12, 2025– – ORLADEYO would be the first targeted oral prophylactic therapy for patients with HAE under the age of...
BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors
BioCryst Pharmaceuticals, Inc. BCRX on Monday reported first-quarter sales of $145.50 million, up 52.7% year over year, beating the consensus of $126.87 million.
BioCryst: Strong Opportunity For A Double With A Proven Therapy
BioCryst Pharmaceuticals' flagship product ORLADEYO shows remarkable growth, maintaining a persistent upward trajectory since its launch in 2020, and is expected to continue into 2025. Despite heavy r...
BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2025 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie Gayer ...
BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update
—Q1 2025 ORLADEYO net revenue of $134.2 million (+51 percent y-o-y)— —Full year 2025 ORLADEYO revenue guidance increased to $580 million to $600 million— —Company now expects to be profitable for full...
BioCryst Appoints Steve Frank to Board of Directors
RESEARCH TRIANGLE PARK, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed healthcare investment banking leader Steve Fr...
BioCryst to Report First Quarter 2025 Financial Results on May 5
RESEARCH TRIANGLE PARK, N.C., April 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2025 financial results on ...
BioCryst to Present at Upcoming Investor Conference
RESEARCH TRIANGLE PARK, N.C., April 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 24th Annual Needham Virtual Heal...
BioCryst: Orladeyo's Expansion Is Just Getting Started
BioCryst Pharmaceuticals, a rare disease biotech, shows strong revenue growth from ORLADEYO, a healthy cash position, and a promising pipeline, making it an attractive investment. Despite a net loss, ...
BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up
BioCryst Pharmaceuticals stock rose 9% since September, driven by strong Orladeyo sales and raised revenue guidance for 2025 to $535-$550 million. Orladeyo's convenience over injectable therapies is s...
BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical
I initially rated BioCryst a "Sell" in November 2023, but am now upgrading to "Hold" as the company has outperformed my expectations, despite competitive pressures. Orladeyo, BioCryst's main revenue s...
BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2024 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2024 Earnings Conference Call February 24, 2025 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie ...
BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings
On Monday, BioCryst Pharmaceuticals, Inc. BCRX released results from an interim analysis of the ongoing APeX-P trial.
BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones
—ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)—